bilateral Babinski's signs, and diminished sensation in the left arm and leg (See Table 1 
1

able, a subset of patients develops a progressive clinical course associated with marked neurologic impairment
She tolerated the acute phase of her BMT well with no clinical exacerbation of her MS, and no GVHD. Followand significant morbidity. BMT has been proposed as a treatment for such patients based on preclinical data up neurological evaluations were done at 4 and 12 months following BMT. During this time she had no clinical as well as clinical observations in other autoimmune diseases. We report clinical and MRI findings in an MS exacerbations of her MS. At four months post-BMT, the patient reported subjective improvement in conjugative eye patient, later diagnosed with CML, and treated with an allogeneic BMT.
movements and in her left-sided sensory deficit. Neurologic examination demonstrated improved sensory perception to Keywords: multiple sclerosis; allogeneic BMT; autoimmune disease pinprick on the left. At 12 months her memory is improved and thought processes are better organized. Her internuclear ophthalmoplegia, hyper-reflexia, Babinski's signs, and sensory deficits are resolved. Her MRI at 12 months revealed Case report no remaining enhancing lesions, as well as no new lesions (Figures 3 and 4) . She remains in hematologic remission A 46-year-old woman had a 29 year history of relapsing with no signs of GVHD, and is off all immunosuppresand remitting MS. Her symptoms included recurrent right sive medications. optic neuritis, episodic vertigo, persistent left-sided sensory abnormalities, and progressive decline in motor skills, balance, and memory. She had comorbid migraines and Discussion chronic daily headaches. She was diagnosed with CML in chronic phase and underwent high-dose chemotherapy with This patient did not experience worsening of her MS sympbusulfan and cyclophosphamide followed by allogeneic toms during either the acute phase of BMT or through 14 marrow stem cell rescue from her HLA-matched brother in April 1995. Graft-versus-host disease (GVHD) prophylaxis Table 1 Neurologic findings before and after BMT consisted of methotrexate given on days 1, 3, 6 and 11 post-transplant, and cyclosporine beginning the day before underway.
2 There are significant potential risks of performing BMT in this population including profound and prolonged immunosuppression, poor tolerance of fever and months of follow-up. Furthermore, she has noted symptomatic improvement and neurological examination is now infection, and possible adverse effects of high-dose chemotherapy upon the central nervous system. Furthermore, normal other than the pale right optic nerve. Her MRI scan remains stable with no evidence of new lesions.
BMT for MS in humans is complicated by the fact that there is an increased familial risk of MS, and some BMT has been proposed as treatment for patients with asymptomatic family members of MS patients have abnorReferences mal MRI scans and/or CSF findings. Thus, there is a theoretical concern regarding the use of related donors for treat- risks of using allogeneic and autologous BMT in humans
